Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Relief of symptoms associated with seasonal allergic rhinitis and nasal congestion in adults and children 12 years and older
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Fexofenadine: 14.4 hours in healthy adults (range 11-15 h); pseudoephedrine: 5-8 hours (p H-dependent urinary excretion may prolong to 14-16 h in alkaline urine).
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Fexofenadine is minimally metabolized by the liver (≤5% via CYP3A4); pseudoephedrine is partially metabolized by hepatic N-demethylation and undergoes renal excretion.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Fexofenadine: 95% excreted unchanged in feces (biliary) and 5% in urine. Pseudoephedrine: 90% excreted unchanged in urine; remainder undergoes hepatic N-demethylation.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Fexofenadine: 60-70% bound to plasma proteins (albumin and α1-acid glycoprotein). Pseudoephedrine: negligible binding (<5%).
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Fexofenadine: 3.3 L/kg (large Vd, extensive tissue distribution); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water).
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Fexofenadine: 33% oral bioavailability (first-pass effect minimal, but absorption incomplete). Pseudoephedrine: ~90% oral bioavailability.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For mild to moderate impairment (Cr Cl 30-80 m L/min): fexofenadine dose adjustment recommended (not to exceed 60 mg once daily), but pseudoephedrine accumulation may occur; use alternative product. Not studied in ESRD.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); caution.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Children under 12 years: not recommended. For children ≥12 years: same as adult dosing: 1 tablet every 12 hours with water.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Elderly patients may be more sensitive to CNS effects and anticholinergic effects of pseudoephedrine. Not recommended due to increased risk of adverse reactions; consider alternative therapy. If used, monitor closely.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
None.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Cardiovascular effects: hypertension, arrhythmias, palpitations, tachycardia, myocardial infarction, stroke (especially with pre-existing cardiovascular disease or concomitant use with other sympathomimetics).,Central nervous system stimulation: nervousness, dizziness, insomnia, tremor, seizures (may be exacerbated in patients with seizure disorders).,Increased intraocular pressure: contraindicated in narrow-angle glaucoma.,Urinary retention: use with caution in patients with prostate hypertrophy or obstructive uropathy.,Thyroid disorders: may aggravate hyperthyroidism; use with caution.,Diabetes mellitus: may increase blood glucose; monitor in diabetic patients.,Acute allergic reactions: discontinue if severe hypersensitivity occurs.,Renal impairment: fexofenadine clearance reduced; avoid use in severe renal impairment (Cr Cl <30 m L/min).,Elderly: more sensitive to adverse effects; use with caution.,Drug interactions: MAO inhibitors (hypertensive crisis); antihypertensives (reduced effect); alcohol/CNS depressants (additive effects).
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Hypersensitivity to fexofenadine, pseudoephedrine, or any component of the formulation.,Severe hypertension or coronary artery disease.,Narrow-angle glaucoma.,Urinary retention (e.g., due to bladder neck obstruction or prostatic hyperplasia).,Severe renal impairment (Cr Cl <30 m L/min).,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Avoid alcohol, which can increase drowsiness. Grapefruit juice may reduce absorption of fexofenadine; avoid concurrent intake. Taking with high-fat meal may slow absorption but not affect overall efficacy.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and third trimesters: Risk of uterine contractions and fetal hypoxia due to pseudoephedrine vasoconstriction; avoid in preeclampsia.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Fexofenadine: low excretion in breast milk (M/P ratio not established); pseudoephedrine: excreted in milk, may cause irritability and sleep disturbances in infants. Use caution, consider risk-benefit.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
No specific dose adjustments recommended; use lowest effective dose for shortest duration due to altered pharmacokinetics (increased plasma volume, decreased GFR).
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Allegra-D 12 Hour contains fexofenadine (antihistamine) and pseudoephedrine (decongestant). Pseudoephedrine can cause insomnia, so advise taking the last dose early in the evening. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use with caution in hyperthyroidism, diabetes, and prostatic hypertrophy. Do not exceed recommended dose; extended-release formulation must be swallowed whole.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Take this medication by mouth with or without food, usually every 12 hours.,Swallow the tablet whole; do not crush, chew, or break it.,Do not take more than 2 tablets in 24 hours.,Avoid taking at bedtime to prevent difficulty sleeping.,Do not take with other products containing pseudoephedrine or other decongestants.,Stop use and ask a doctor if symptoms do not improve within 7 days or are accompanied by fever.,Keep out of reach of children.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is: Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.